Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alaunos Therapeutics Inc. manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, ZHU, JIANJIAN, who is the busiest examiner with 1 busiest examiner pending action. The portfolio is concentrated in 1 distinct art unit, indicating a specific pharmaceutical or biological focus.
For a practitioner, the entire pending workload is subject to the examination style of ZHU, JIANJIAN. The presence of 1 distinct art unit means the practitioner can focus on the specific technical standards of that unit. Since there is only 1 pending office action, the company's current US patent strategy is highly focused on this single case.
The lack of multiple distinct examiners means there is no opportunity to compare different examination approaches within this portfolio. Practitioners should carefully review the history of ZHU, JIANJIAN to anticipate potential challenges. This narrow scope simplifies the management of the portfolio but increases the risk associated with a single examiner's perspective within the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834112 | Methods for Activation and Expansion of T Cells | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18834112 | Methods for Activation and Expansion of T Cells | ZHU, JIANJIAN | 1631 | §102§103DP | Non-Final OA | — | Pending | Jul 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlaunos Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jianjian Zhu has the most, with 1 of Alaunos Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
